Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06648200
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer: a Single-center, Randomized Trial
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Interventions
Etoposide JS004 Platinum Toripalimab
Updated 1 time since 2024 Last updated: Oct 16, 2024 Started: Nov 1, 2024 Primary completion: Sep 1, 2030 Completion: Sep 1, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06648200, this PHASE2 trial focuses on Small Cell Lung Cancer Extensive Stage and Small Cell Lung Cancer Recurrent and remains actively recruiting participants. Sponsored by Shanghai Pulmonary Hospital, Shanghai, China, it has been updated 1 time since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai Pulmonary Hospital, Shanghai, China
Data source: Shanghai Pulmonary Hospital, Shanghai, China
For direct contact, visit the study record on ClinicalTrials.gov .